R&D
Global Research & Development Center

Oncogen's worls-class Advanced R&D centre, spread over 40,000 sq.ft is involved in development of high quality API and Formulations. A team of over 50 world-class, well-experienced scientists are at the fore-front of our development activities.

LEARN MORE
PRODUCTS
Targeted Portfolio

Oncogen Specializes in complex, niche and technology-intensive Oncology drugs that meet stringent global quality standards. We have a strong pipeline of more than 15 API's and over 10 formulation products for US market to be launched simultaneously in most of the global markets.

LEARN MORE
ALLIANCES
Partnerships

Building firm alliances across a variety of non-existing expertise plays a significant role in the development of our product pipeline and enables us to better serve consumers and healthcare providers who need and rely on our products for treatments.

LEARN MORE

CONTRACT
DEVELOPMENT

CONTRACT
MANUFACTURING

IN LICENSING

TECHNOLOGY
TRANSFER

STRATEGIC ALLIANCE

OUT-LICENSING

PRODUCT
PARTNERSHIPS

COLLABORATION
PLATFORM
Manufacturing Excellence

Oncogen's API and Formulation manufacturing plants are completely automated, respiratory free, OEB 5 category high containment facilities designed by international experts following stringent regulatory requirements by authorities across the globe including USFDA, EMA, PIC/S and WHO. These containment by Design (CbD) facilities have capabilities to develop Social oral as well as Injectable products for regulated & key emerging markets.

LEARN MORE
News And Insights
NEWS
Scitech pilih Malaysia buka pusat R&D API

Malaysia terus menjadi pilihan pelabur asing sebagai hab pengeluar produk farmaseutikal menerusi pembukaan Pusat Pembangunan dan Kajian (R&D) Onkologi Bahan Aktif Farmaseutikal (API) oleh syarikat dari Dubai, Scitech Ltd menerusi anak syarikatnya, Oncogen Pharma Sdn Bhd.

READ MORE
NEWS
Scitech pilih Malaysia buka pusat R&D API

Malaysia terus menjadi pilihan pelabur asing sebagai hab pengeluar produk farmaseutikal menerusi pembukaan Pusat Pembangunan dan Kajian (R&D) Onkologi Bahan Aktif Farmaseutikal (API) oleh syarikat dari Dubai, Scitech Ltd menerusi anak syarikatnya, Oncogen Pharma Sdn Bhd.

READ MORE
NEWS
Scitech pilih Malaysia buka pusat R&D API

Malaysia terus menjadi pilihan pelabur asing sebagai hab pengeluar produk farmaseutikal menerusi pembukaan Pusat Pembangunan dan Kajian (R&D) Onkologi Bahan Aktif Farmaseutikal (API) oleh syarikat dari Dubai, Scitech Ltd menerusi anak syarikatnya, Oncogen Pharma Sdn Bhd.

READ MORE
twitter